Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Novel351k logo — Global solutions for accessible biosimilars.

Novel351k

Global solutions for accessible biosimilars.

United States United States 1 employees Biopharma, Biotechnology

General Information

Company Name Novel351k
Location United States United States +1
Employees 1
Industries Biopharma, Biotechnology
Social

Get notified when Novel351k moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Novel351k

Novel351k offers global solutions for accessible biosimilars with its innovative and flexible technology. With over 30 years of experience in creating new drugs, chemicals, biologicals, and biosimilars, the company guarantees the lowest cost and time to market. Novel351k's platform accelerates the approval of biosimilars, providing innovation and speed to existing commercial models. The company focuses on reducing the time for pharma and biotech partners to manage their portfolios and development costs efficiently. Their core strength is complemented by decades of experience working through the novelty of the regulatory path. Novel351k operates in the Biopharma and Biotechnology industries. The company's founded date and headquarter location are not specified, and there is no information about the last investment and last investment investors at present.

Taxonomy: biosimilars development, regulatory compliance, pharmaceutical innovation, biotech partnerships, drug approval process, commercialization strategy, biologicals development, chemical development, biopharmaceuticals, drug portfolio management

No funding data available for Novel351k yet.

Get notified when Novel351k raises funding

Novel351k Alternatives & Competitors

Novel351k vs
Mid-Atlantic BioTherapeutics (MABT)
Mid-Atlantic BioTherapeutics (MABT) United States

MABT: Impacting disease with innovative treatments.

Series Unknown
4 employees
Life Sciences, Pharmaceutical
Novel351k vs
Formycon AG
Formycon AG Germany

The Biosimilar Experts

Post Ipo Equity
171 employees
Biopharma
Novel351k vs
Dandu Biosciences Private Limited
Dandu Biosciences Private Limited India

Passion for Science

26 employees
Biotechnology, Manufacturing

FAQ About Novel351k

Global solutions for accessible biosimilars.
Novel351k is headquartered in United States.
Novel351k operates in the following industries: Biopharma, Biotechnology.
Novel351k has approximately 1 employees.
Top alternatives and competitors to Novel351k include Mid-Atlantic BioTherapeutics (MABT), Formycon AG, Dandu Biosciences Private Limited, ChemDiv, Inc., SQ Innovation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Novel351k and Mid-Atlantic BioTherapeutics (MABT) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Novel351k and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes